Abstract: The invention relates to the use of Ginkgo biloba for the treatment of mitochondrial diseases of genetic origin and more particularly mitochondrial encephalomyopathies.
Type:
Grant
Filed:
July 26, 2007
Date of Patent:
January 17, 2012
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Arnold Munnich, François Clostre, Mehemed Ouzid
Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
Type:
Grant
Filed:
September 10, 2008
Date of Patent:
December 13, 2011
Assignee:
IPSEN Pharma, S.A.S.
Inventors:
Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
Abstract: The invention concerns the use of a therapeutic composition comprising at least one pyrrolobenzodiazepine derivative combined with fludarabine for treating cancer and more particularly hematological diseases.
Abstract: A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.
Type:
Grant
Filed:
December 16, 2005
Date of Patent:
September 13, 2011
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Marie-Odile Galcera-Contour, Dennis Bigg, Grégoire Prevost, Alban Sidhu
Abstract: A catalytic lactide and glycolide copolymerization system comprising a trifluoromethane sulfonate as a catalyst and copolymerization additive and a copolymerization process.
Type:
Grant
Filed:
December 11, 2008
Date of Patent:
August 16, 2011
Assignee:
IPSEN Pharma S.A.S.
Inventors:
Blanca Martin-Vaca, Anca Dumitrescu, Lidija Vranicar, Jean-Bernard Cazaux, Didier Bourissou, Roland Cherif-Cheikh, Frédéric Lacombe
Abstract: The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
Type:
Application
Filed:
September 29, 2009
Publication date:
July 21, 2011
Applicants:
Ipsen Pharma S.A.S., Commissariat a L'Energie Atomique Aux Energies Alternatives (C.E.A.), Le Centre National De Recherche Scientifique (CNRS)
Inventors:
Marie-Thérèse Paternostre, Jean-Christophe Cintrat, Céline Valery, Stéphane Roux, Bernard Rousseau, Maarten Ijsselstijn, Roland Cherif-Cheikh, Frank Artzner
Abstract: The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and ? is —NR46R47 or —OR48, R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.
Type:
Application
Filed:
March 21, 2011
Publication date:
July 14, 2011
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Pierre-Etienne CHABRIER DE LASSAUNIERE, Jeremiah Harnett, Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau
Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
Abstract: The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and ? is —NR46R47 or —OR48, R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.
Type:
Grant
Filed:
December 11, 2007
Date of Patent:
June 7, 2011
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Pierre-Etienne Chabrier De Lassauniere, Jeremiah Harnett, Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, Jacques Lannoy, Christophe Thurieau
Abstract: The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier; and parenterally administering said pharmaceutical composition to a subject by injection, wherein said composition automatically forms a gel after interaction with the patient's bodily fluids and releases said peptide carrier and said agent or agents continuously within the patient over an extended period.
Type:
Grant
Filed:
March 4, 2003
Date of Patent:
May 17, 2011
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Jacques-Pierre Moreau, Roland Cherif-Cheikh
Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
Abstract: The present invention relates to new 4-phenyl-1,3-azole derivatives having the general formula (I) wherein R1, R2, R3, R4, X, A, B, and n are variable, in a racemic form, an enantiomeric form or any combinations thereof. These compounds exhibit affinity for cannabinoid receptors and may therefore be used as drugs to treat or prevent pathological states and diseases in which one or more of these receptors are involved. The invention also relates to pharmaceutical compositions containing said products and to the use thereof to prepare a drug.
Abstract: The present invention relates to the use of a system composed of a base and of a sulphonamide, as a catalyst for the ring-opening (co)polymerization of lactones. The present invention also relates to novel sulphonamides and to a process for the ring-opening (co)polymerization of lactones comprising the use of sulphonamides in combination with a base as a catalytic system.
Type:
Application
Filed:
April 29, 2009
Publication date:
March 3, 2011
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
Didier Bourissou, Blanca Martin-Vaca, Aurelie Alba, Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado
Abstract: Disclosed are peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, methods of using such analogues to treat mammals and pharmaceutical compositions useful therefor comprising said analogues.
Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
Type:
Application
Filed:
April 27, 2009
Publication date:
February 17, 2011
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
Abstract: The present invention relates to stable parenteral formulations comprising a new class of compounds, which is a non proteinic compound, a method for preparing such formulations as well as the use of certain compounds for stabilizing these formulations.
Abstract: A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
Abstract: A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.
Type:
Application
Filed:
August 3, 2010
Publication date:
December 16, 2010
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Marie-Odile Galcera-Contour, Grégoire Prevost, Alban Sidhu